← back to search

Joe Dan Dunn

The University of Texas MD Anderson Cancer Center · US
Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include Cancer Genomics and Diagnostics, RNA modifications and cancer, Cancer Immunotherapy and Biomarkers, and Head and Neck Cancer Studies.
h-index
19
citations
3,656
works
114
NIH funding
primary concept
email

Recent publications

Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.
2025cited by 5position: middledoi
Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers.
2025cited by 1position: middledoi
Supplementary Table S10 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S18 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S8 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S15 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S9 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Figures S1-S18 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S19 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Data from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S13 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S17 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S16 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S11 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S14 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S12 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S7 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Table S20 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Tables S1-S6 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025cited by 0position: middledoi
Supplementary Figures S1-S6 and Tables S1-S5 from Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration
2025cited by 0position: middledoi
Data from Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration
2025cited by 0position: middledoi
Supplementary Video: HPV and Heterocateny from Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration
2025cited by 0position: middledoi
Supplementary Table S17. from Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers
2025cited by 0position: middledoi
Supplementary Table S25. from Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers
2025cited by 0position: middledoi
Supplementary Fig. S12. from Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers
2025cited by 0position: middledoi
Supplementary Fig. S3. from Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers
2025cited by 0position: middledoi
Supplementary Fig. S9. from Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers
2025cited by 0position: middledoi
Supplementary Fig. S11. from Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers
2025cited by 0position: middledoi
Supplementary Fig. S1. from Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers
2025cited by 0position: middledoi
Supplementary Table S15. from Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers
2025cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 67 papers (2023–2025)Keiko Akagi · American Society of Human Genetics67 papers (2023–2025)Sara Goodwin · MUSC Hollings Cancer Center67 papers (2023–2025)Kevin R. Coombes · Georgia Cancer Center at Augusta University67 papers (2023–2025)Maura Gillison · Communities In Schools of Orange County67 papers (2023–2025)David E. Symer · United States Department of Veterans Affairs67 papers (2023–2025) · 67 papers (2023–2025)LI SHEN · The University of Texas MD Anderson Cancer Center44 papers (2025–2025) · 44 papers (2025–2025)Jing Wang · Air Force Medical University44 papers (2025–2025) · 44 papers (2025–2025)Nusrat Israr Khan · The University of Texas MD Anderson Cancer Center44 papers (2025–2025) · 44 papers (2025–2025)Shiming Jiang · The University of Texas MD Anderson Cancer Center44 papers (2025–2025)Qi Wang · Capital Medical University44 papers (2025–2025)Jamie L. Hutchins · 44 papers (2025–2025) · 44 papers (2025–2025)K. Jagannadha Sastry · The University of Texas MD Anderson Cancer Center44 papers (2025–2025)Fritz J. Sedlazeck · Baylor University23 papers (2023–2025)Darawalee Wangsa · National Institutes of Health23 papers (2023–2025)